SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-23-042677
Filing Date
2023-09-05
Accepted
2023-09-05 16:18:31
Documents
6
Period of Report
2023-10-02

Document Format Files

Seq Description Document Type Size
1 DEF14A ny20010189x2_def14a.htm DEF 14A 250252
2 logo_rvl.jpg GRAPHIC 17241
3 ny20010189x2_pc01.jpg GRAPHIC 785297
4 ny20010189x2_pc02.jpg GRAPHIC 710508
5 sig_bmarkison.jpg GRAPHIC 14961
6 sig_sschroppe.jpg GRAPHIC 21837
  Complete submission text file 0001140361-23-042677.txt   2384838
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38709 | Film No.: 231236006
SIC: 2834 Pharmaceutical Preparations